ClinicalTrials.gg
CompletedNCT00157040Updated Apr 27, 2021

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

A Phase 2/3 interventional study of Antihemophilic factor, recombinant, manufactured protein-free in Hemophilia A, sponsored by Baxalta now part of Shire. Completed at 12 sites in 3 countries. Open to participants aged Up to 6 Years. Per ClinicalTrials.gov, last updated 2021-04-27.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 3 months after the study started (first participant enrolled Jun 2002, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
Up to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A — 1 open to participants now, 2 under way, none of them phase 3. antihemophilic factor, human recombinant · Hemophilia A.

Enrollment
10th of 21
50 · median 50
Started
2002
the only one that year
Phase 2/3
3 of 21
none open now
Registered
1st of 21
by date
Lead sponsor
8 of 21
Baxalta now part of Shire

Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, this one is the 10th largest by enrollment, is the only one that started in 2002, is one of 3 in phase 2/3, and was the 1st registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About antihemophilic factor, human recombinant

antihemophilic factor, human recombinant: first FDA approval 1992 (Bioclate (Armour), Recombinate), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: Up to 6 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether rAHF-PFM is effective and safe in the treatment of children with hemophilia A. The study consists of 2 parts. Part 1 of the study is a pharmacokinetic evaluation, and Part 2 is an evaluation of efficacy and safety.

03

Conditions studied

  • Hemophilia A

Browse trials for

Keywords

  • Factor VIII Deficiency
04

Who can participate

Ages eligible
Up to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is less than 6 years of age
  • Severe or moderately-severe hemophilia A as defined by a baseline factor VIII level \<= 2%, documented at screening or on the basis of historical data (e.g., at hemophilia diagnosis)
  • Documented medical history of at least 50 exposure days for treatment with all other factor VIII products
  • Subject's parent or legally authorized representative has provided

Exclusion criteria

Exclusion Criteria:

  • Detectable inhibitor to factor VIII measured in the screening sample by the local or central hemostasis laboratory
  • History of inhibitor to factor VIII at any time prior to screening
  • Subject has any one of the following laboratory abnormalities at the time of screening:

    1. count \< 100,000/mm3
    2. concentration \< 10 g/dL (100 g/L)
    3. serum creatinine > 1.5 times the for age
    4. total > 2 times the ULN for age
  • Subject has an inherited or acquired hemostatic defect other than hemophilia A (e.g., platelet dysfunction secondary to uremia, liver failure, von Willebrand's Disease)
  • Subject has known to RECOMBINATE rAHF
  • Subject is currently participating in another drug study or has participated in any clinical study involving an investigational drug within 30 days of study entry
  • Subject is identified by the investigator as being unable or unwilling to cooperate with study procedures
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The terminal phase half-life of Recombinant Antihemophilic Factor (rAHF-PFM)

    Terminal phase half-life of rAHF-PFM was to be determined using the biphasic linear regression model.

    Time frame: Within 30 minutes prior to the pharmacokinetic infusion and at 1 hour ± 5 minutes, 9 ± 1 hour, 24 ± 2 hours, and 48 ± 2 hours after the infusion

07

Study locations

12 sites
  • Children´s Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Emory University, Department of Pediatrics
    Atlanta, Georgia 30322, United States
  • Children´s Memorial Hospital
    Chicago, Illinois 60614, United States
  • Comprehensive Bleeding Disorders Center
    Peoria, Illinois 61614, United States
  • Indiana Hemophilia and Thrombosis Center
    Indianapolis, Indiana 46260, United States
  • University of Iowa Hospitals and Clinics, Iowa Regional Hemophilia Center, Department of Pediatrics
    Iowa City, Iowa 52242, United States
  • University of Michigan Hemophilia Treatment Center
    Ann Arbor, Michigan 48109, United States
  • Children´s Hospital of Michigan
    Detroit, Michigan 48201, United States
  • Children´s Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • University of Texas Health Science Center
    Houston, Texas 77030, United States
  • Hospital for Sick Children, Division of Hematology/Oncology
    Toronto, Ontario M5G 1X8, Canada
  • University Pediatric Hospital
    San Juan, 00927, Puerto Rico
08

References and documents

Publications

  • Shapiro A, Gruppo R, Pabinger I, Collins PW, Hay CR, Schroth P, Casey K, Patrone L, Ehrlich H, Ewenstein BM. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. Expert Opin Biol Ther. 2009 Mar;9(3):273-83. doi: 10.1517/14712590902729392. PubMed 19216617 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2002 to primary completion in Jan 2005, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
StartActual
Jun 7, 2002
Primary completionActual
Jan 4, 2005
CompletionActual
Jan 4, 2005
Last update
Apr 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00157040
Responsible party
Sponsor
First posted
Sep 12, 2005
Start date
Jun 7, 2002
Primary completion
Jan 4, 2005
Completion
Jan 4, 2005
Last update
Apr 27, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Antihemophilic factor, human recombinant · F8 protein, human

Start the discussion